ArmaGen Technologies, Inc. Expands Patent Portfolio With Issuance of Two Additional U.S. Patents

Based on the work of Dr. , these new patents reinforce ARMAGEN's already dominant intellectual property position for the Company's novel platform for delivery of therapeutics across the BBB into the central nervous system utilizing endogenous receptor-mediated transporters.

http://www.biospace.com/news_story.aspx?StoryID=307647&full=1